The Association Between Aspirin Resistance and Extend and Severity of the Coronary Atherosclerosis

Kahraman, Serkan; Doğan, Ali; Zıyrek, Murat; Usta, Emrah; Demiröz, Önder; Çıftçı, Çavlan

doi:10.14744/nci.2017.26779

Cited by 8 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…But this fact, that is, the presence of a large amount of hyperagregation in patients against the background of taking the drug ASA, indicates a low level of thrombogenic potential in patients. ADP-induced aggregated thrombocytosis can lead to myocardial infarction and occlusion, and the indicator of spontaneous platelet aggregation can again be a reliable marker of myocardial infarction and the risk of occlusion [19,22].…”

Section: Discussionmentioning

confidence: 99%

Evaluation Of Platelet Aggregation Activity Depending on The Duration of Antiplatelet Administration in Patients with Coronary Heart Disease

Iskandarovna¹

2022

Journal of Pharmaceutical Negative Results

View full text Add to dashboard Cite

To study the aggregation activity of platelets in patients with ischemic heart disease depending on the long-term intake of acetylsalicylic acid (ASA). Material and methods. The study included: 116 patients with coronary artery disease with stable angina pectoris, taking a standard dose of aspirin 75 mg/day. during various terms. Patients with SSN were divided into 4 groups according to the duration of taking ASA. Platelet aggregation was measured using a laser platelet aggregation analyzer Alat-2 Biol, with computer processing according to the AGGR program. Adenosine diphosphate (ADP) in concentrations of 0.1, 1.0, 5.0 mmol/l was used as an inductor. The results of the study of patients taking ASA for more than 5 years showed that spontaneous aggregation and ADP-induced platelet aggregation were higher than in patients taking the drug for less than 5 years. Statistically significant differences were observed when compared with a group of patients taking ASA for less than a year (spontaneous aggregation of 1.7±0.09 (p<0.05), 0.1 μm ADP-induced aggregation of 6.58±0.86 (p<0.05), 1.0 μm ADP-induced aggregation of 16.51±1.63 (p<0.01), 5.0 μm ADP-induced aggregation 58.44±3.72 (p<0.01). Conclusion. Thus, the results showed that with an increase in the duration of aspirin intake, there was a change in both spontaneous and ADP-induced platelet aggregation with a statistically significant increase.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation Of Platelet Aggregation Activity Depending on The Duration of Antiplatelet Administration in Patients with Coronary Heart Disease

Iskandarovna¹

2022

Journal of Pharmaceutical Negative Results

View full text Add to dashboard Cite

show abstract

“…Furthermore, we utilized the Gensini scoring system to value the stenosis of each coronary artery, as it had been described previously. [21]…”

Section: Methodsmentioning

confidence: 99%

Potential predictors for mental stress-induced myocardial ischemia in patients with coronary artery disease

Yang

Zhang

et al. 2019

Chinese Medical Journal

View full text Add to dashboard Cite

Background: Mental stress-induced myocardial ischemia (MSIMI) is closely associated with adverse cardiac events in patients with coronary artery disease (CAD) and we aimed to determine whether biomarkers and blood pressure could be potential predictors of MSIMI. Methods: This study enrolled 82 patients with documented CAD between June 1, 2017 and November 9, 2017. Patient blood samples were obtained at resting period and at the end of mental arithmetic. Then, patients were assigned to MSIMI positive group and MSIMI negative group. The main statistical methods included linear regression, receiver operating characteristic (ROC) curves, and logistic regression. Results: Patients with CAD with MSIMI had significantly greater median resting N-terminal pro-brain natriuretic peptide (NT-proBNP, 141.02 [45.85–202.76] pg/mL vs . 57.95 [27.06–117.64] pg/mL; Z = −2.23, P = 0.03) and mean systolic blood pressure (SBP) (145.56 ± 16.87 mmHg vs . 134.92 ± 18.16 mmHg, Z = −2.13, P = 0.04) when compared with those without MSIMI. After 5-min mental stress task, those who developed MSIMI presented higher elevation of median post-stressor high sensitivity cardiac troponin I (hs-cTnI, 0.020 [0.009–0.100] ng/mL vs . 0.009 [0.009–0.010] ng/mL; Z = −2.45, P = 0.01), post-stressor NT-proBNP (138.96 [39.93–201.56] pg/mL vs . 61.55 [25.66–86.50] pg/mL; Z = −2.15, P = 0.03) compared with those without MSIMI. Using the ROC curves, and after the adjustment for basic characteristics, the multiple logistic regression analysis showed that patients presenting a post-stressor hs-cTnI ≥ 0.015 ng/mL had seven-fold increase in the risk of developing MSIMI (odds ratio [OR]: 7.09; 95% confidence interval [CI]: 1.65–30.48; P = 0.009), a rest NT-proBNP ≥ 80.51 pg/mL had nearly eight-fold increase (OR: 7.85; 95% CI: 1.51–40.82; P = 0.014), a post-stressor NT-proBNP ≥ 98.80 pg/mL had 35-fold increase (OR: 34.96; 95% CI: 3.72–328.50; P = 0.002), a rest SBP ≥ 129.50 mmHg had 11-fold increase (OR: 11.42; 95% CI: 1.21–108.17; P = 0.034). Conclusions: The present study shows that CAD patients with higher hs-cTnI level, and/or greater NT-proBNP and/or SBP are at higher risk of suffering from MSIMI when compared with those without MSIMI, indicating that hs-cTnI, NT-proBNP, SBP might be potential predictors of MSIMI.

show abstract

“…В настоящее время доказано, что назначение антиагрегантных препаратов для первичной и вторичной профилактики острых сердечно-сосудистых событий является обязательным компонентом фармакотерапии ИБС, оно входит в клинические рекомендации разных уровней [5-7, 12, 20-22]. Ацетилсалициловая кислота (АСК), клиническая эффективность которой доказана многочисленными клиническими исследованиями, остается самым распространенным и доступным препаратом, ингибирующим агрегацию тромбоцитов [12,19,20].…”

Section:  введениеunclassified

Features of Platelet Aggregation Activity Depending on Aspirin Intake in Patients with Coronary Heart Disease

Аляви¹,

Ходжанова²,

Сабиржанова³

2023

Кардиология В Беларуси

View full text Add to dashboard Cite

Цель. Изучение агрегационной активности тромбоцитов у пациентов с ишемической болезнью сердца (ИБС) в зависимости от длительности приема ацетилсалициловой кислоты (АСК). Материалы и методы. В исследование включены 116 пациентов с ИБС со стабильной стенокардией напряжения, принимавших стандартную дозу АСК 75 мг/сут в течение различных сроков. Пациенты со стабильной стенокардией напряжения были разделены на 4 группы в зависимости от длительности приема АСК: менее года, от 1 года до 5 лет, более 5 лет. Измерение агрегации тромбоцитов проводилось при помощи лазерного анализатора агрегации тромбоцитов «Алат-2 Биола» с компьютерной обработкой по программе AGGR. В качестве индуктора использовался аденозиндифосфат (АДФ) в концентрациях 0,1, 1,0, 5,0 мкмоль/л. В качестве критерия резистентности к АСК использован уровень спонтанной агрегации тромбоцитов >1,5 отн. ед., уровень агрегации тромбоцитов с 5,0 мкмоль АДФ >72% и наличие фазы высвобождения на кривой агрегации тромбоцитов. При этом в 32,6% случаев у пациентов с ИБС, принимающих АСК, наблюдалась аспиринорезистентность. Результаты. Результаты исследования агрегации тромбоцитов у пациентов, принимавших АСК более 5 лет, показали, что спонтанная агрегация и АДФ-индуцированная агрегация были выше, чем у пациентов с приемом препарата менее 5 лет. Статистически значимые различия наблюдались при сравнении с группой пациентов, принимавших АСК менее года (спонтанная агрегация 1,7±0,09 (р<0,05); 0,1 мкм АДФ-индуцированная агрегация 6,58±0,86 (р<0,05); 1,0 мкм АДФ-индуцированная агрегация 16,51±1,63 (р<0,01); 5,0 мкм АДФ-индуцированная агрегация 58,44±3,72 (р<0,01)). Выводы. Полученные результаты показали, что с увеличением продолжительности приема АСК наблюдалось изменение как спонтанной, так и индуцированной АДФ агрегации тромбоцитов со статистически значимым увеличением. Purpose. To study platelet aggregation activity in patients with ischemic heart disease depending on the duration of acetylsalicylic acid (ASA) intake. Materials and methods. The study included 116 patients with coronary artery disease with stable angina pectoris who were taking a conventional ASA dose of 75 mg/day over different periods. Patients with stable angina pectoris (SАР) were divided into 4 groups according to the duration of ASA intake. Platelet aggregation was measured using a laser platelet aggregation analyzer Alat-2 Biol, with AGGR program computer processing. Adenosine diphosphate (ADP) in concentrations of 0.1, 1.0, 5.0 mmol/l was used as an inductor. The level of spontaneous platelet aggregation >1.5 rel. units, the level of platelet aggregation with 5.0 μmol ADP >72% and the presence of a release phase on the platelet aggregation curve were used as ASA resistance criterion. At the same time, aspirin resistance was observed in 32.6% of cases in patients with coronary artery disease taking ASA. Results. The results of the study of patients taking ASA for more than 5 years showed that in such patients both spontaneous and ADP-induced platelet aggregations were higher than in patients taking ASA for less than 5 years. Statistically significant differences were observed when compared with a group of patients taking ASA for less than a year (spontaneous aggregation of 1.7±0.09 (p<0.05), 0.1 μm ADP-induced aggregation of 6.58±0.86 (p<0.05), 1.0 μm ADP-induced aggregation of 16.51±1.63 (p<0.01), 5.0 μm ADP-induced aggregation 58.44±3.72 (p<0.01)). Conclusion. Thus, the results showed that with increasing ASA intake duration both spontaneous and ADP-induced platelet aggregation alterations were observed with a statistically significant increase.

show abstract

The Association Between Aspirin Resistance and Extend and Severity of the Coronary Atherosclerosis

Cited by 8 publications

References 22 publications

Evaluation Of Platelet Aggregation Activity Depending on The Duration of Antiplatelet Administration in Patients with Coronary Heart Disease

Evaluation Of Platelet Aggregation Activity Depending on The Duration of Antiplatelet Administration in Patients with Coronary Heart Disease

Potential predictors for mental stress-induced myocardial ischemia in patients with coronary artery disease

Features of Platelet Aggregation Activity Depending on Aspirin Intake in Patients with Coronary Heart Disease

Contact Info

Product

Resources

About